Atlas Trials

Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

Clinical trial NCT06075238 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06075238
Sponsor
Sichuan University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Leukemia, Lymphoid
Start date
2023-10-01
Primary completion
2024-09-30
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.